Pharma grade cellulose powder market seen reaching $2.1 billion by 2030

The Business Research Company says the pharma grade cellulose powder market is set to grow at about 6.1% annually through 2030, driven by demand in pharmaceuticals, personal care, and health-focused products. North America is expected to remain the largest regional market, while microcrystalline cellulose stays the biggest product segment.

Why it matters: - Pharma grade cellulose powder is a core excipient in tablet, capsule, and other drug formulations, so growth in this market tracks broader demand for medicines and higher-performance drug delivery. - The market is also benefiting from rising use in personal care, nutraceuticals, and clean-label products, widening its role beyond pharmaceuticals. - The report pegs the market at $2.1 billion by 2030, underscoring a specialized but strategically important slice of the pharma supply chain.

What happened: - The Business Research Company released its Pharma Grade Cellulose Powder Market Global Market Report 2026, covering market size, trends, and forecasts through 2035. - The report says the market is expected to grow at a 6.1% CAGR and surpass $2 billion by 2030. - The company also says the market will reach $2.1 billion by 2030. - The report includes links for a free sample and the full report: the sample request and the detailed report.

The details: - Microcrystalline cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, and hydroxypropyl cellulose make up the main product types in the market. - Microcrystalline cellulose is projected to remain the largest segment in 2030, with 42% share and about $0.9 billion in revenue. - The report links microcrystalline cellulose leadership to compressibility, flow properties, and use in direct-compression tablet manufacturing. - The market is segmented by function into binding agents, thickening agents, stabilizers, disintegrants, and coating agents. - Applications include pharmaceuticals, nutraceuticals, cosmetics, and other specialized uses. - End users include contract research organizations, pharmaceutical and biotechnology companies, academic and research institutions, dietary supplement manufacturers, and the food and beverage industry. - North America is projected to be the largest regional market by 2030 at $0.71 billion, up from $0.55 billion in 2025, for a 5% CAGR. - The U.S. market is forecast to rise from $0.50 billion in 2025 to $0.65 billion in 2030, also at a 5% CAGR. - JRS Pharma held the largest global share in 2025 at 2%. - The ten largest companies together accounted for about 20% of total revenue in 2025, pointing to a fragmented competitive landscape. - The report names JRS Pharma, FMC Corporation, Asahi Kasei Corporation, DFE Pharma, Roquette Frères, Sigachi Industries Ltd., Rayonier Advanced Materials, Dow Chemical Company, Shin-Etsu Chemical Co. Ltd., and Colorcon as major players with 2% shares each in 2025.

Between the lines: - Growth is being driven by multiple end markets at once, which reduces reliance on any single pharmaceutical category. - Personal care demand is one of the more important non-drug growth engines because cellulose powder serves as a thickener, stabilizer, absorber, and texture enhancer. - Pharmaceutical demand remains the base case, supported by chronic disease prevalence, higher healthcare spending, generic drugs, and over-the-counter medicines. - The move toward plant-derived, clean-label, and transparent ingredients is reinforcing premium excipient demand. - Continuous manufacturing is emerging as a competitive differentiator, with DFE Pharma and Gericke launching a platform in February 2026 for formulation and process development. - Moderate barriers to entry remain in place because suppliers must meet stringent quality standards and global pharmacopeial requirements.

What's next: - The market’s next phase of growth will likely come from more advanced excipient design, broader use in modified-release and patient-focused formulations, and continued expansion in solid oral dosage forms. - The combined value of MCC, CMC, HPMC, and HPC is expected to rise by more than $0.54 billion between 2025 and 2030. - MCC and HPMC are each projected to add about $0.2 billion, while CMC is expected to add $0.1 billion and HPC about $0.04 billion. - Leading suppliers are expected to lean on partnerships, product upgrades, and regional expansion to defend share as demand increases for compliant, high-purity ingredients. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards, hotspots infographics, and updated graphics and tables.

The bottom line: - Pharma grade cellulose powder is shifting from a niche excipient into a broader growth market tied to pharmaceuticals, personal care, and consumer health trends.